- Home
- LOT vs AVBP Comparison
LOT vs AVBP Comparison
Compare LOT & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOT
- AVBP
- Stock Information
- Founded
- LOT 1948
- AVBP 2021
- Country
- LOT China
- AVBP United States
- Employees
- LOT N/A
- AVBP N/A
- Industry
- LOT
- AVBP
- Sector
- LOT
- AVBP
- Exchange
- LOT NYSE
- AVBP NYSE
- Market Cap
- LOT 956.3M
- AVBP 862.8M
- IPO Year
- LOT N/A
- AVBP 2024
- Fundamental
- Price
- LOT $2.22
- AVBP $20.99
- Analyst Decision
- LOT
- AVBP Strong Buy
- Analyst Count
- LOT 0
- AVBP 8
- Target Price
- LOT N/A
- AVBP $39.00
- AVG Volume (30 Days)
- LOT 70.7K
- AVBP 467.6K
- Earning Date
- LOT 06-25-2025
- AVBP 08-13-2025
- Dividend Yield
- LOT N/A
- AVBP N/A
- EPS Growth
- LOT N/A
- AVBP N/A
- EPS
- LOT N/A
- AVBP N/A
- Revenue
- LOT $844,090,000.00
- AVBP N/A
- Revenue This Year
- LOT $40.53
- AVBP $66.25
- Revenue Next Year
- LOT $87.99
- AVBP N/A
- P/E Ratio
- LOT N/A
- AVBP N/A
- Revenue Growth
- LOT 1.33
- AVBP N/A
- 52 Week Low
- LOT $1.06
- AVBP $15.47
- 52 Week High
- LOT $7.42
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- LOT 49.56
- AVBP 44.84
- Support Level
- LOT $2.09
- AVBP $22.12
- Resistance Level
- LOT $2.75
- AVBP $23.27
- Average True Range (ATR)
- LOT 0.15
- AVBP 1.43
- MACD
- LOT -0.02
- AVBP -0.38
- Stochastic Oscillator
- LOT 12.88
- AVBP 7.84
About LOT LOTUS TECHNOLOGY INC
Lotus Technology Inc is a battery electric vehicle (BEV) maker that designs, develops, and sells BEV lifestyle vehicles under the Lotus brand. The Group is also a distributor that sells luxury sports cars under the Lotus brand. It also provides other sales and ancillary services to customers.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.